Literature DB >> 19184333

Elevated endogenous GABA concentration attenuates glutamate-glutamine cycling between neurons and astroglia.

Jehoon Yang1, Jun Shen.   

Abstract

In this study, the relationship between endogenous brain GABA concentration and glutamate-glutamine cycling flux (V (cyc)) was investigated using in vivo (1)H and (1)H{(13)C} magnetic resonance spectroscopy techniques. Graded elevations of brain GABA levels were induced in rat brain after administration of the highly specific GABA-transaminase inhibitor vigabatrin (gamma-vinyl-GABA). The glial-specific substrate [2-(13)C]acetate and (1)H{(13)C} magnetic resonance spectroscopy were used to measure V (cyc) at different GABA levels. Significantly reduced V (cyc) was found in rats pretreated with vigabatrin. The reduction in group mean V (cyc) over the range of GABA concentrations investigated in this study (1.0 +/- 0.3-5.1 +/- 0.5 micromol/g) was found to be nonlinear: Delta V (cyc)/V (cyc) = [GABA (micromol/g)](-0.35 )- 1.0 (r (2) = 0.98). The results demonstrate that V (cyc) is modulated by endogenous GABA levels, and that glutamatergic and GABAergic interactions can be studied in vivo using noninvasive magnetic resonance spectroscopy techniques.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19184333      PMCID: PMC2845912          DOI: 10.1007/s00702-009-0186-0

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  41 in total

1.  A history of the use of anticonvulsants as mood stabilizers in the last two decades of the 20th century.

Authors:  R M Post; K D Denicoff; M A Frye; R T Dunn; G S Leverich; E Osuch; A Speer
Journal:  Neuropsychobiology       Date:  1998-10       Impact factor: 2.328

2.  Determination of the rate of the glutamate/glutamine cycle in the human brain by in vivo 13C NMR.

Authors:  J Shen; K F Petersen; K L Behar; P Brown; T W Nixon; G F Mason; O A Petroff; G I Shulman; R G Shulman; D L Rothman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

3.  The rate of turnover of cortical GABA from [1-13C]glucose is reduced in rats treated with the GABA-transaminase inhibitor vigabatrin (gamma-vinyl GABA).

Authors:  D Manor; D L Rothman; G F Mason; F Hyder; O A Petroff; K L Behar
Journal:  Neurochem Res       Date:  1996-09       Impact factor: 3.996

4.  Effectiveness of vigabatrin against focally evoked pilocarpine-induced seizures and concomitant changes in extracellular hippocampal and cerebellar glutamate, gamma-aminobutyric acid and dopamine levels, a microdialysis-electrocorticography study in freely moving rats.

Authors:  I Smolders; G M Khan; H Lindekens; S Prikken; C A Marvin; J Manil; G Ebinger; Y Michotte
Journal:  J Pharmacol Exp Ther       Date:  1997-12       Impact factor: 4.030

5.  In vivo 13C NMR measurements of cerebral glutamine synthesis as evidence for glutamate-glutamine cycling.

Authors:  N R Sibson; A Dhankhar; G F Mason; K L Behar; D L Rothman; R G Shulman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

6.  Metabolic precursors and compartmentation of cerebral GABA in vigabatrin-treated rats.

Authors:  N E Preece; S Cerdán
Journal:  J Neurochem       Date:  1996-10       Impact factor: 5.372

Review 7.  Glutamate, GABA and epilepsy.

Authors:  H F Bradford
Journal:  Prog Neurobiol       Date:  1995-12       Impact factor: 11.685

8.  The effect of chronic treatment with the GABA transaminase inhibitors gamma-vinyl-GABA and ethanolamine-O-sulphate on the in vivo release of GABA from rat hippocampus.

Authors:  M Qume; P S Whitton; L J Fowler
Journal:  J Neurochem       Date:  1995-05       Impact factor: 5.372

9.  Preferential utilization of acetate by astrocytes is attributable to transport.

Authors:  R A Waniewski; D L Martin
Journal:  J Neurosci       Date:  1998-07-15       Impact factor: 6.167

10.  Glutamate release in human cerebral cortex and its modulation by 5-hydroxytryptamine acting at h 5-HT1D receptors.

Authors:  G Maura; M Marcoli; M Tortarolo; G C Andrioli; M Raiteri
Journal:  Br J Pharmacol       Date:  1998-01       Impact factor: 8.739

View more
  6 in total

1.  In vivo detection of intermediate metabolic products of [1-(13) C]ethanol in the brain using (13) C MRS.

Authors:  Yun Xiang; Jun Shen
Journal:  NMR Biomed       Date:  2011-02-11       Impact factor: 4.044

2.  Metabolomic analyses of vigabatrin (VGB)-treated mice: GABA-transaminase inhibition significantly alters amino acid profiles in murine neural and non-neural tissues.

Authors:  Dana C Walters; Erland Arning; Teodoro Bottiglieri; Erwin E W Jansen; Gajja S Salomons; Madalyn N Brown; Michelle A Schmidt; Garrett R Ainslie; Jean-Baptiste Roullet; K Michael Gibson
Journal:  Neurochem Int       Date:  2019-02-26       Impact factor: 3.921

3.  In Vivo Detection of CPP-115 Target Engagement in Human Brain.

Authors:  Andrew P Prescot; Steven R Miller; Gary Ingenito; Rebekah S Huber; Douglas G Kondo; Perry F Renshaw
Journal:  Neuropsychopharmacology       Date:  2017-07-25       Impact factor: 7.853

4.  Effect of acute psychological stress on prefrontal GABA concentration determined by proton magnetic resonance spectroscopy.

Authors:  Gregor Hasler; Jan Willem van der Veen; Christian Grillon; Wayne C Drevets; Jun Shen
Journal:  Am J Psychiatry       Date:  2010-07-15       Impact factor: 18.112

5.  Neuroprotective effects of various doses of topiramate against methylphenidate-induced oxidative stress and inflammation in isolated rat amygdala: the possible role of CREB/BDNF signaling pathway.

Authors:  Majid Motaghinejad; Manijeh Motevalian; Reza Falak; Mansour Heidari; Mahshid Sharzad; Elham Kalantari
Journal:  J Neural Transm (Vienna)       Date:  2016-09-24       Impact factor: 3.575

6.  Investigation of cortical glutamate-glutamine and γ-aminobutyric acid in obsessive-compulsive disorder by proton magnetic resonance spectroscopy.

Authors:  Helen B Simpson; Dikoma C Shungu; James Bender; Xiangling Mao; Xiaoyan Xu; Mark Slifstein; Lawrence S Kegeles
Journal:  Neuropsychopharmacology       Date:  2012-08-01       Impact factor: 7.853

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.